Menu
PTAB Blog
Biosimilars Blog
RF 360

Publications

Precise. Insightful. Skilled
Search Publications
View All

Publications

Biosimilars in the US: The Next Frontier for Big Pharma

Rothwell Figg attorneys Brian A. Tollefson and Seth E. Cockrum published an article in the August 2017 issue of Financier Worldwide Magazine titled "Biosimilars in the US: the next frontier for big pharma." Read the entire…
More

Political Correctness: A 21st Century Stronghold Now Under Siege by Trademarks

The scene is set. Your mark is judged as disparaging. Can the Examining Attorney reject it? Fear not, because the Supreme Court in Tam cried: “Free Speech!” In recent years, the delimitation between First Amendment…
More

  • Obviousness May Soon Return To High Court

    Attorneys Derek F. Dahlgren and Spencer J. Johnson were featured in IP Law360 for their article entitled "Obviousness May Soon Return to High Court."  To read the full article, please visit: https://www.law360.com/articles/935776/obviousness-may-soon-return-to-high-court. …
    More

  • Steps to Follow When Sued for Patent Infringement

    Rothwell Figg attorneys Brian A. Tollefson and John D. Higgins published an article in the June 2017 issue of Financier Worldwide Magazine titled "Steps to follow when sued for patent infringement." Read the entire article here: https://www.financierworldwide.com/steps-to-follow-when-sued-for-patent-infringement#.WS2G_JLyvAW. …
    More

  • Rothwell Figg Attorneys Participate in PTAB Roundtable

    Rothwell Figg attorneys Martin M. Zoltick and Derek F. Dahlgren are featured in a roundtable article entitled "Five Years of the Patent Trial and Appeal Board" in which they discuss how the Patent Trial and Appeal…
    More

  • View All Publications
Biosimilars Blog

BiosimilarsIP.com features articles, updates, and analysis on regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA). The posts, authored and edited by attorneys in the firm’s Biologics and Biosimilars practice group, track regulatory issues and events, provide analysis of legal decisions from federal courts and from the Patent Trial and Appeal Board, and offer updates on current news and events related to biologics and biosimilars. Our team understands the manufacturing, regulatory, and legal requirements of the field, and has the experience and the technical knowledge to handle the most sophisticated matters, including issues related to regulatory approval, securing patent rights, counseling and opinions, post-grant challenges, and asserting or defending against patents in litigation. To learn more, please visit www.BiosimilarsIP.com.

Visit Blog
PTAB Blog

Authored and edited by attorneys in the firm’s Post-Grant Trial practice group, PTABLaw.com provides updates, articles, and analysis about the Patent Trial and Appeal Board (PTAB), the Court of Appeals for the Federal Circuit, and the American Invents Act.  Our group has considerable experience handling inter partes review (IPR), covered business method (CBM) review, and post-grant review (PGR) proceedings before the PTAB.  Our depth of knowledge and expertise with handling matters before the PTAB is unique, as many of the attorneys in our group have substantial experience in handling interference proceedings and reexaminations, and in prosecuting applications before the Office, as well as extensive litigation experience in the federal courts. To learn more, please visit www.PTABLaw.com.

Visit Blog